ArticleScientific reports2026
Design, green synthesis, and bioevaluation of 1,3-thiazole-sulfonamide hybrids as antimicrobial and anti-inflammatory agent.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents the design and green synthesis of a novel series of 1,3-thiazole sulfonamide hybrids 4, 6a–j using microwave irradiation. The synthetic method achieved high yields (87–92%) with short reaction times (8–15 min) and minimal use of toxic solvents, aligning with green chemistry principles. The structures of all products were confirmed via IR, 1H NMR, 13C NMR, and elemental analysis. The synthesized compounds were evaluated for their in vitro antimicrobial activity against Staphylococcus aureus and Escherichia coli, as well as for their anti-inflammatory activities. Compound 6h exhibited the highest antibacterial activity, with inhibition zones of 32 mm and 28 mm against S. aureus and E. coli, respectively. In anti-inflammatory assays, compounds 6h, 6i, and 6j demonstrated superior efficacy, achieving inhibition percentages of up to 97.98%, 95.06%, and 95.53%, respectively at 500 µg/mL, these results are comparable to those of the reference drug, diclofenac sodium (85.16%). A structure-activity relationship (SAR) study revealed that the presence of electron-donating groups on the phenyl ring significantly enhances both antimicrobial and anti-inflammatory activities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.